Targeting immunosuppression for cancer therapy

Ghirelli, Cristina
Hagemann, Thorsten

Barts Cancer Institute, John Vane Science Centre, London, United Kingdom.

Address correspondence to: Thorsten Hagemann, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, 3rd Floor, London, EC1M 6BQ, United Kingdom. Phone: 442078825795; Fax: 442078826110; E-mail: [email protected].

Journal of Clinical Investigation 123(6):p 2355-2357, June 3, 2013. | DOI: 10.1172/JCI69999

Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.